Pharmacogenetic workshop: TPMT and NUDT15 testing in adult acute lymphoblastic leukaemia patients

In April 2023, a guideline was released to provide dosing recommendations for 6-mercaptopurine (6-MP) in adult acute lymphoblastic leukaemia patients based on their TPMT and NUDT15 genotypes. The new guideline can be found on the BOPA website.

This educational webinar explains:

• The role of 6-MP in the treatment of ALL and it’s mechanism of action
• The role of TPMT and NUDT15 in the metabolism and detoxification of 6-mercaptopurine
• Common variant alleles that contribute to reduced or absent TPMT/NUDT15 enzyme activity and how this is linked to increased myelosuppression in your patients
• The importance of genetic testing for this patient cohort and how to implement dose modifications based upon a patient’s phenotype

Download a copy of the presentation slides here.